Top

Open Access 25-04-2024 | Glioma | CLINICAL GUIDES IN ONCOLOGY

SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Authors: María Ángeles Vaz-Salgado, Belén Cigarral García, Isaura Fernández Pérez, Beatriz Jiménez Munárriz, Paula Sampedro Domarco, Ainhoa Hernández González, María Vieito Villar, Raquel Luque Caro, María Luisa Villamayor Delgado, Juan Manuel Sepúlveda Sánchez

Published in: Clinical and Translational Oncology

Abstract

The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilber MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;74(14):1344–55. https://doi.org/10.1056/NEJMoa1500925.CrossRef

Mellinghoff IK, Van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601. https://doi.org/10.1056/NEJMoa2304194.CrossRefPubMed

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.CrossRefPubMedPubMedCentral

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1–95. https://doi.org/10.1093/neuonc/noac202.CrossRefPubMedPubMedCentral

Ostrom QT, Fahmideh MA, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21(11):1357–75. https://doi.org/10.1093/neuonc/noz123.CrossRefPubMedPubMedCentral

Myung S-K, Ju W, McDonnell DD, Lee YJ, Kazinets G, Cheng C-T, et al. Mobile phone use and risk of tumors: a meta-analysis. J Clin Oncol. 2009;27(33):5565–72. https://doi.org/10.1200/JCO.2008.21.6366.CrossRefPubMed

Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, et al. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ. 2012;344:e1147. https://doi.org/10.1136/bmj.e1147.CrossRefPubMedPubMedCentral

Deltour I, Auvinen A, Feychting M, Johansen Ch, Klaeboe L, Sankila R, et al. Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology. 2012;23(2):301–7. https://doi.org/10.1097/EDE.0b013e3182448295.CrossRefPubMed

Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316–24. https://doi.org/10.1093/neuonc/nos208.CrossRefPubMedPubMedCentral

10.

Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44. https://doi.org/10.1086/321805.CrossRefPubMed

11.

Pouratian N, Asthagiri A, Jagannathan J, Shaffrey ME, Schiff D. Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol. 2007;3(11):628–39. https://doi.org/10.1038/ncpneuro0634.CrossRefPubMed

12.

Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014;19(4):403–13. https://doi.org/10.1634/theoncologist.2013-0345.CrossRefPubMedPubMedCentral

13.

Komori T. Grading of adult diffuse gliomas according to the 2021 WHO classification of tumors of the central nervous system. Lab Invest. 2022;102(2):126–33. https://doi.org/10.1038/s41374-021-00667-6.CrossRefPubMed

14.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–86. https://doi.org/10.1038/s41571-020-00447-z.CrossRefPubMed

15.

Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics acta neuropathological communications. BioMed Central. 2020;8(1):1–22. https://doi.org/10.1186/s40478-020-00902-z.CrossRef

16.

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–84. https://doi.org/10.1200/JCO.2002.08.121.CrossRefPubMed

17.

Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41. https://doi.org/10.3171/JNS/2008/109/11/0835.CrossRefPubMed

18.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–98. https://doi.org/10.1056/NEJMoa1402121.CrossRef

19.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560–6. https://doi.org/10.1212/WNL.0b013e3181f96282.CrossRefPubMed

20.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679–93. https://doi.org/10.1007/s00401-015-1409-0.CrossRefPubMed

21.

Jiang H, Cui Y, Wang J, Lin S. Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system. Oncotarget. 2017;8(12):20354–61. https://doi.org/10.18632/oncotarget.13555.CrossRefPubMed

22.

Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125(3):503–30. https://doi.org/10.1007/s11060-015-1867-1.CrossRefPubMed

23.

Hollon T, Hervey-Jumper SL, Sagher O, Orringer DA. Advances in the surgical management of low-grade glioma. Semin Radiat Oncol. 2015;25(3):181–8. https://doi.org/10.1016/j.semradonc.2015.02.007.CrossRefPubMedPubMedCentral

24.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103–12. https://doi.org/10.1093/neuonc/nox176.CrossRefPubMed

25.

Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol. 2006;24(18):2707–14. https://doi.org/10.1200/JCO.2005.04.3414.CrossRef

26.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant Procarbazine, lomustine, and Vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol. 2006;24(18):2715–22. https://doi.org/10.1200/JCO.2005.04.6078.CrossRefPubMed

27.

Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45. https://doi.org/10.1200/JCO.2007.13.9337.CrossRefPubMed

28.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, et al. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019;6(4):249–58. https://doi.org/10.1093/nop/npy034.CrossRefPubMed

29.

Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10(3):224–31. https://doi.org/10.1007/s11910-010-0105-7.CrossRefPubMedPubMedCentral

30.

Jakola AS, Murmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881–8. https://doi.org/10.1001/jama.2012.12807.CrossRefPubMed

31.

Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–8. https://doi.org/10.1093/annonc/mdx230.CrossRefPubMedPubMedCentral

32.

Ius T, Ng S, Young JS, Tomasino B, Polano M, Ben-Israel D, et al. The benefit of early surgery on overall survival in incidental low-grade glioma patients: a multicenter study. Neuro Oncol. 2022;24(4):624–38. https://doi.org/10.1093/neuonc/noab210.CrossRefPubMed

33.

Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016;130(2):269–82. https://doi.org/10.1007/s11060-016-2110-4.CrossRefPubMed

34.

Stummer W, Pichlmeir U, Meinel T, Wiestler OD, Zanella F, Reulen H-J, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401. https://doi.org/10.1016/S1470-2045(06)70665-9.CrossRefPubMed

35.

De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559–65. https://doi.org/10.1200/JCO.2011.38.4818.CrossRefPubMed

36.

Pallud J, Fontaire D, Duffau H, Mandonnet E, Sanai N, Taillandier L, et al. Natural history of incidental world health organization grade II gliomas. Ann Neurol. 2010;68(5):727–33. https://doi.org/10.1002/ana.22106.CrossRefPubMed

37.

Zhang Z-Y, Chan AK-Y, Ng H-K, Ding X-J, Li Y-X, Shi Z-F, et al. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014;7(12):8627–36.PubMedPubMedCentral

38.

Vernooij MW, Ikram MA, Tanghe HL, Vincent AJPE, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821–8. https://doi.org/10.1056/NEJMoa070972.CrossRefPubMed

39.

Weber F, Knopf H. Incidental findings in magnetic resonance imaging of the brains of healthy young men. J Neurol Sci. 2006;240(1–2):81–4. https://doi.org/10.1016/j.jns.2005.09.008.CrossRefPubMed

40.

Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007;84(2):189–99. https://doi.org/10.1007/s11060-007-9356-9.CrossRefPubMed

41.

Morris Z, Whiteley WN, Longstreth WT, Weber F, Lee Y-C, Tsushima Y, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339:b3016. https://doi.org/10.1136/bmj.b3016.CrossRefPubMedPubMedCentral

42.

Zeng L, Mei Q, Li H, Ke C, Yu J, Chen J. A survival analysis of surgically treated incidental low-grade glioma patients. Sci Rep. 2021;11(1):8522. https://doi.org/10.1038/s41598-021-88023-y.CrossRefPubMedPubMedCentral

43.

Riva M, Bello L. Low-grade glioma management: a contemporary surgical approach. Curr Opin Oncol. 2014;26(6):615–21. https://doi.org/10.1097/CCO.0000000000000120.CrossRefPubMed

44.

Karim ABMF, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2022;52(2):316–24. https://doi.org/10.1016/s0360-3016(01)02692-x.CrossRef

45.

Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20(9):2267–76. https://doi.org/10.1200/JCO.2002.09.126.CrossRefPubMed

46.

Indelicato DJ, Rotondo RL, Uezono H, Sandler ES, Aldana PR, Ranalli NJ, et al. Outcomes following proton therapy for pediatric low-grade glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):149–56. https://doi.org/10.1016/j.ijrobp.2019.01.078.CrossRefPubMed

47.

Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus Procarbazine, lomustine (CCNU), and Vincristine in high-risk low-grade glioma. J Clin Oncol. 2010;38(29):3407–17. https://doi.org/10.1200/JCO.19.02983.CrossRef

48.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–32. https://doi.org/10.1016/S1470-2045(16)30313-8.CrossRefPubMedPubMedCentral

49.

McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700–7. https://doi.org/10.1227/01.NEU.0000325729.41085.73. (author reply 707–708).CrossRefPubMed

50.

Ramakrishna R, Hebb A, Barber J, Rostomily R, Silbergeld D. Outcomes in reoperated low-grade gliomas. Neurosurgery. 2015;77(2):175–84. https://doi.org/10.1227/NEU.0000000000000753.CrossRefPubMed

51.

Khalafallah AM, Jimenez AE, Romo CG, Olayinka Kamson D, Kleinberg L, Weingart J, et al. Quantifying the utility of a multidisciplinary neuro-oncology tumor board. J Neurosurg. 2020;135(1):87–92. https://doi.org/10.3171/2020.5.JNS201299.CrossRefPubMed

52.

Gaudino S, Giordano C, Magnani F, Cottonaro S, Infante A, Sabatino G, et al. Neuro-oncology multidisciplinary tumor board: the point of view of the neuroradiologist. J Pers Med. 2022;12(2):135. https://doi.org/10.3390/jpm12020135.CrossRefPubMedPubMedCentral

53.

Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21(4):646–51. https://doi.org/10.1200/JCO.2003.01.009.CrossRefPubMed

54.

Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6. https://doi.org/10.1093/annonc/mdg502.CrossRefPubMed

55.

Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, et al. Vorasidenib, a dual inhibitor of mutant idh1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021;27(16):4491–9. https://doi.org/10.1158/1078-0432.CCR-21-0611.CrossRefPubMedPubMedCentral

56.

de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib/II trial. Neuro Oncol. 2023;25(1):146–56. https://doi.org/10.1093/neuonc/noac139.CrossRefPubMed

57.

Rodon J, Damian S, Furgan M, Garcia-Donas J, Imai H, Italiano A, et al. CT016: clinical and translational findings of Pemigatinib in previously treated solid tumors with activating FGFR1–3 alterations in the FIGHT-207 study. Cancer Res. 2023;83(8):CT016. https://doi.org/10.1158/1538-7445.AM2023-CT016.CrossRef

58.

Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau H-T, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase i dose-expansion study. Cancer Discov. 2022;12(2):402–15. https://doi.org/10.1158/2159-8290.CD-21-0697.CrossRefPubMed

59.

Kilbrurn L, Khoung-Quang D-A, Nysom K, Landi D, Ziegler D, Hernáiz Driever P, et al. LGG-09. Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma ARM of the phase 2 FIREFLY-1 (PNOC026) study. Neuro Oncol. 2023;25(Suppl 1):i57. https://doi.org/10.1093/neuonc/noad073.219.PMCID:PMC10260080.CrossRef

60.

Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl 8):viii23–30.CrossRefPubMedPubMedCentral

61.

NCCN Guideline Central Nervous System Cancers. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed Feb 2024.

62.

Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, et al. Recent developments and future directions in adult lower-grade gliomas: society for neuro-oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. Neuro Oncol. 2019;21(7):837–53. https://doi.org/10.1093/neuonc/noz033.CrossRefPubMedPubMedCentral

63.

Larsen J, Wharton SB, Mckevitt F, Romanowski Ch, Bridgewater C, Zaki H, et al. Low grade glioma”: an update for radiologists. Br J Radiol. 2017;90(1070):20160600. https://doi.org/10.1259/bjr.20160600.CrossRefPubMedPubMedCentral

64.

Fathallah-Shaykh HM, DeAtkine A, Coffe E, Khayat E, Bag AK, Han X, et al. Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: a retrospective observational study. PLoS Med. 2019;16(5):e1002810. https://doi.org/10.1371/journal.pmed.1002810.CrossRefPubMedPubMedCentral

65.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015;17(9):1188–98. https://doi.org/10.1093/neuonc/nov095.CrossRefPubMedPubMedCentral

66.

Jo J, van den Bent MJ, Nabors B, Wen PY, Schiff D. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas. Neuro Oncol. 2022;24(7):1035–47. https://doi.org/10.1093/neuonc/noac031.CrossRefPubMedPubMedCentral

67.

Miller JJ, Loebel F, Jurtli TA, Tummala SS, Williams EA, Batchelor TT, et al. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019;21(5):669–77. https://doi.org/10.1093/neuonc/noz016.CrossRefPubMedPubMedCentral

68.

Rimmer B, Bolnykh I, Dutton L, Lewis J, Burns R, Gallagher P, et al. Health-related quality of life in adults with low-grade gliomas: a systematic review. Qual Life Res. 2023;32(3):625–51. https://doi.org/10.1007/s11136-022-03207-x.CrossRefPubMed

69.

Rimmer B, Dutton L, Lewis J, Burns R, Gallaguer P, Willians S, et al. Ways ahead: developing a supported self-management programme for people living with low- and intermediate-grade gliomas - a protocol for a multi-method study. BMJ Open. 2020;10(7): e041465. https://doi.org/10.1136/bmjopen-2020-041465.CrossRefPubMedPubMedCentral

70.

Roberts M, Northmore T, Shires J, Taylor P, Hayhurst C. Diffuse low grade glioma after the 2016 WHO update, seizure characteristics, imaging correlates and outcomes. Clin Neurol Neurosurg. 2018;175:9–15. https://doi.org/10.1016/j.clineuro.2018.10.001.CrossRefPubMed

Title: SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
Authors: María Ángeles Vaz-Salgado
Belén Cigarral García
Isaura Fernández Pérez
Beatriz Jiménez Munárriz
Paula Sampedro Domarco
Ainhoa Hernández González
María Vieito Villar
Raquel Luque Caro
María Luisa Villamayor Delgado
Juan Manuel Sepúlveda Sánchez
Publication date: 25-04-2024
Publisher: Springer International Publishing
Keywords: Glioma
Glioma
Glioma
Astrocytoma
Astrocytoma
Astrocytoma
Oligodendroglioma
Radiotherapy
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03456-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer